Aflibercept biosimilar (Sam Chun Dang Pharm)

阿柏西普生物类似药（参天堂）

Report date: 2026/05/08 20:02:52

Base Information

Drug NameAflibercept biosimilar (Sam Chun Dang Pharm)
Drug Alias NameEiyzeySCD-411
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaRetinal Vein OcclusionWet age-related macular degeneration +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUnited States +[14] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSam Chun Dang Pharm Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesApotexSam Chun Dang Pharm Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaRetinal Vein OcclusionWet age-related macular degeneration +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A